The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory gout.

Similarly, mean SU reductions were significantly higher for SEL-212 vs pegloticase (−7.32 and −4.89 mg/dl, respectively; P = 0.0185) in participants with tophi during months 3 and 6 combined, but narrowly missed achieving significance in those without tophi ( Supplementary Table S6 , available at Rheumatology online).

also in 1 other paper

In the subgroup without tophi, however, the reduction in SU narrowly missed statistical significance.

also in 86 other papers